Preclinical Models of Adrenocortical Cancer

16Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Adrenocortical cancer is an aggressive endocrine malignancy with an incidence of 0.72 to 1.02 per million people/year, and a very poor prognosis with a five-year survival rate of 22%. As an orphan disease, clinical data are scarce, meaning that drug development and mechanistic research depend especially on preclinical models. While a single human ACC cell line was available for the last three decades, over the last five years, many new in vitro and in vivo preclinical models have been generated. Herein, we review both in vitro (cell lines, spheroids, and organoids) and in vivo (xenograft and genetically engineered mouse) models. Striking leaps have been made in terms of the preclinical models of ACC, and there are now several modern models available publicly and in repositories for research in this area.

Cite

CITATION STYLE

APA

Sedlack, A. J. H., Hatfield, S. J., Kumar, S., Arakawa, Y., Roper, N., Sun, N. Y., … del Rivero, J. (2023, June 1). Preclinical Models of Adrenocortical Cancer. Cancers. MDPI. https://doi.org/10.3390/cancers15112873

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free